Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients (ISS OBS T-004)

Clinical Trial ID NCT01359800

PubWeight™ 3.53^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01359800

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.	J Infect Dis	2005	1.23
2	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.	PLoS One	2010	1.13
3	Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.	AIDS	2006	1.12
4	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.	Vaccine	2009	0.97
5	The preventive phase I trial with the HIV-1 Tat-based vaccine.	Vaccine	2009	0.95
6	Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.	J Infect Dis	2003	0.95
7	The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.	AIDS	2008	0.95
8	Challenges in HIV Vaccine Research for Treatment and Prevention.	Front Immunol	2014	0.93
9	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.	Retrovirology	2014	0.92
10	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.	Retrovirology	2015	0.89
11	Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.	Rev Recent Clin Trials	2009	0.87
12	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.	Expert Opin Biol Ther	2015	0.79